| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 03/24/2010 | EP2166111A1 Prognostic factor in sarcoma, and metastasis inhibitor |
| 03/24/2010 | EP2166095A2 Antisense oligonucleotides capable of inhibiting the formation of capillary tubes in endothelial cells |
| 03/24/2010 | EP2166087A2 FAD4, FAD5, FAD5-2 et FAD6, fatty acid desaturase family members and uses thereof |
| 03/24/2010 | EP2166010A1 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| 03/24/2010 | EP2166008A1 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| 03/24/2010 | EP2166000A1 7-, 8- and 9-substituted tetracycline compounds |
| 03/24/2010 | EP2165715A1 Therapeutic agent for cancer, and method for treatment of cancer |
| 03/24/2010 | EP2165710A1 Tyrosine kinase receptor Tyro3 as a therapeutic target in the treatment of a bladder tumor |
| 03/24/2010 | EP2165708A2 New pyrazole derivatives as transforming growth factor (tgf) inhibitors |
| 03/24/2010 | EP2165605A1 Use of a ribonuclease of the T2 family having actin-binding activity for inhibiting and/or reversing proliferation |
| 03/24/2010 | EP2164874A1 Chimeric and humanized anti-cd44 antibodies that mediate cancer cell cytotoxicity |
| 03/24/2010 | EP2164871A2 Anti-cd20 therapeutic compositions and methods |
| 03/24/2010 | EP2164870A1 Polypeptides and polynucleotides for artemin and related ligands, and methods of use thereof |
| 03/24/2010 | EP2164865A2 Compounds for the modulation of huntingtin aggregation, methods and means for identifying such compounds |
| 03/24/2010 | EP2164856A1 Processes related to making capecitabine |
| 03/24/2010 | EP2164850A2 N-substituted azaindoles and methods of use |
| 03/24/2010 | EP2164849A2 Pyridopyrazine derivatives, process of manufacturing and uses thereof |
| 03/24/2010 | EP2164833A2 Quinazolinamide derivatives |
| 03/24/2010 | EP2164506A2 Specific therapy and medicament using integrin ligands for treating cancer |
| 03/24/2010 | EP2164495A1 Use of derivatives of 3-oxo-2,3-dihydro-5h-thiazolofý3,2-a¨pyrimidine or of 3-oxo-2,3-dihydro-5h-selenazoloý3,2-a¨pyrimidine or of 3-oxo-1,2,3-trihydro-5h-imidazoloý1,2-a¨pyrimidine for the preparation of pharmaceutical compositions intended for the treatment of cancer |
| 03/24/2010 | EP2164483A2 Transglutaminase inhibitor comprising chlorogenic acid and a method for producing thereof |
| 03/24/2010 | EP2164479A2 New sigma-receptor ligands with anti-apoptotic and/or pro-apoptotic properties over cellular biochemical mechanisms, with neuroprotective, anti- cancer, anti-metastatic and anti-(chronic) inflammatory action |
| 03/24/2010 | EP1839662B1 Antitumor agent |
| 03/24/2010 | EP1710236B1 Derivatives of pyridine and quinoline |
| 03/24/2010 | EP1507562B1 Compositions for radioimmunotherapy of brain |
| 03/24/2010 | EP1389110B1 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| 03/24/2010 | EP1328511B1 Substituted (e)-styryl benzylsulfones for treating proliferative disorders |
| 03/24/2010 | EP1180938B1 Agents, compositions and methods utilizing the same useful in treating or preventing alzheimer disease |
| 03/24/2010 | CN101679988A Fusion proteins binding to growth factors |
| 03/24/2010 | CN101679962A Single-stranded cyclic rna, and method for production thereof |
| 03/24/2010 | CN101679953A Mutant reoviruses and methods of making and using |
| 03/24/2010 | CN101679526A Humanized and chimeric anti-TROP-2 antibodies that mediate cancer cell cytotoxicity |
| 03/24/2010 | CN101679524A Inorxoclonal antibody directed against the human LDL receptor |
| 03/24/2010 | CN101679522A Modulation of tumor microenvironment |
| 03/24/2010 | CN101679510A Composition of a first non-labeled monoclonal antibody binding to a tumor antigen and a non-cross reactive second monoclonal antibody labeled with a NIR fluorescence label |
| 03/24/2010 | CN101679501A methods of treating, diagnosing and detecting fgf21-associated disorders |
| 03/24/2010 | CN101679470A Method for production of sugar oxazoline derivative |
| 03/24/2010 | CN101679456A Thiazoliopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase |
| 03/24/2010 | CN101679448A spiroindolinone derivatives |
| 03/24/2010 | CN101679446A 3,3-spiroindolinone derivatives |
| 03/24/2010 | CN101679439A P70 s6激酶抑制剂 P70 s6 kinase inhibitors |
| 03/24/2010 | CN101679434A 2, 6, 9-substituted purine derivatives having anti proliferative properties |
| 03/24/2010 | CN101679432A Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors |
| 03/24/2010 | CN101679429A 5-aminopyrazol-3-yl-3h-imidazo [4,5-b] pyridine derivatives and their use for the treatment of cancer |
| 03/24/2010 | CN101679426A 9-(pyrazol-3-yl)-9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidaz0[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer |
| 03/24/2010 | CN101679423A Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors |
| 03/24/2010 | CN101679422A Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors |
| 03/24/2010 | CN101679418A [2, 6] naphthyridines useful as protein kinase inhibitors |
| 03/24/2010 | CN101679411A mapk/erk kinase inhibitors |
| 03/24/2010 | CN101679409A New compounds |
| 03/24/2010 | CN101679408A Bicyclic heterocyclic compounds as FGFR inhibitors |
| 03/24/2010 | CN101679401A 2-oxo-3-benzyl-benzoxazol-2-one derivatives and related compounds as MET kinase inhibitors for the treatment of tumors |
| 03/24/2010 | CN101679396A triazolyl aminopyrimidine compounds |
| 03/24/2010 | CN101679395A triazolyl aminopyrimidine compounds |
| 03/24/2010 | CN101679387A Aminopyrimidines useful as kinase inhibitors |
| 03/24/2010 | CN101679386A Aminopyrimidines useful as kinase inhibitors |
| 03/24/2010 | CN101679382A 3-imidazolyl-indoles for the treatment of proliferative diseases |
| 03/24/2010 | CN101679372A Solid forms of a RAF kinase inhibitor |
| 03/24/2010 | CN101679362A 4-{4-[({3-tert-butyl-1-[3-(hydroxymethyl) phenyl]-1h-pyrazol-5-yl } carbamoyl)-amino] -3-fluorophenoxy} -N-methylpyridine-2-carboxamide as well as prodrugs and salts thereof for the treatment of cance |
| 03/24/2010 | CN101679356A Novel crystalline forms of a vegf-r inhibitor |
| 03/24/2010 | CN101679340A antitumoral dihydropyran-2-one compounds |
| 03/24/2010 | CN101679327A Substituted phenoxy aminothiazolones as estrogen related receptor-alpha modulators |
| 03/24/2010 | CN101679322A Substituted phenoxy thiazolidinediones as estrogen related receptor-alpha modulators |
| 03/24/2010 | CN101679321A Triazine derivatives, compositions containing such derivatives, and methods of treatment of cancer and autoimmune diseases using such derivatives |
| 03/24/2010 | CN101679313A Axl kinase inhibitors used in cancer or excess proliferative disease |
| 03/24/2010 | CN101679310A Alkynylpyrimidines as Tie2 kinase inhibitors |
| 03/24/2010 | CN101679306A Heteroarylamide pyrimidone derivatives |
| 03/24/2010 | CN101679304A Pyridazine-, pyridine- and pyrane-derivatives as GPBAR1 agonisis |
| 03/24/2010 | CN101679271A Quinoline derivatives, pharmaceutical compositions comprising them, and their use in treating central nervous system and peripheral diseases |
| 03/24/2010 | CN101679266A PIM kinase inhibitors and methods of their use |
| 03/24/2010 | CN101679264A inhibitors of focal adhesion kinase |
| 03/24/2010 | CN101679256A mono-hydrochloric salts of an inhibitor of histone deacetylase |
| 03/24/2010 | CN101679255A Piperidinones useful in the treatment of inflammation |
| 03/24/2010 | CN101679254A Piperidinones useful in the treatment of inflammation |
| 03/24/2010 | CN101679239A inhibitors of histone deacetylase |
| 03/24/2010 | CN101678215A Sulfonyl amide derivatives for the treatment of abnormal cell growth |
| 03/24/2010 | CN101678214A 芳基醚哒嗪酮衍生物 Aryl ether pyridazinones |
| 03/24/2010 | CN101678123A Compositions that include a hydrophobic compound and a polyamino acid conjugate |
| 03/24/2010 | CN101678121A Modified hydroxypolymer conjugates with killing effect on tumor cells |
| 03/24/2010 | CN101678118A Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications |
| 03/24/2010 | CN101678116A Sialoadhesin-related compositions and methods |
| 03/24/2010 | CN101678109A formulations of deacetylase inhibitors |
| 03/24/2010 | CN101678101A Pharmaceutical compositions capable of inducing apoptosis in tumour cells, useful for diagnosis and treatment of B-chronic lymphocytic leukaemia |
| 03/24/2010 | CN101678082A Methods for promoting protection and regeneration of bone marrow using CXCL9 and anti-CXCL9 antibodies |
| 03/24/2010 | CN101678078A SPARC and methods of use thereof |
| 03/24/2010 | CN101678075A Cell migration, cell infiltration, or neovascularization inhibitor through degradation of function of ptk7 protein |
| 03/24/2010 | CN101678065A Vaccine therapy for choroidal neovascularization |
| 03/24/2010 | CN101678062A Drugs for treating and preventing benign prostatic hyperplasia, prostatitis, impotency, infertility and prostate cancer and a method for the use thereof |
| 03/24/2010 | CN101678059A New use for cannabinoid-containing plant extracts |
| 03/24/2010 | CN101678058A Compositions comprising an extract of tiarella polyphylla or compounds isolated therefrom for preventing and treating cancer diseases |
| 03/24/2010 | CN101678037A Combined use of cholestanol derivative |
| 03/24/2010 | CN101678029A Combination of a purine-based CDK inhibitor with a tyrosine kinase inhibitor and use thereof in the treatment of proliferative disorders |
| 03/24/2010 | CN101678026A 3, 6-disubstituted-imidazo [1, 2-B] pyridazines and 3, 5-disubstituted pyrazolo[1, 5-A] pyrimidines as phosphatidylinositol-3-kinase inhibitors |
| 03/24/2010 | CN101678023A stabilized amorphous forms of imatinib mesylate |
| 03/24/2010 | CN101678020A Quinoxaline derivatives as inhibitors of the tyrosine kinase activity of Janus kinases |
| 03/24/2010 | CN101678013A piperidine/piperazine derivatives |
| 03/24/2010 | CN101678008A Anti-tumor activity of temsirolimus in papillary renal cell cancer |
| 03/24/2010 | CN101678007A gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| 03/24/2010 | CN101678002A Methods of treatment using intravenous formulations comprising temozolomide |
| 03/24/2010 | CN101678001A Combination therapy comprising AZD2171 and AZD6244 or MEK-inhibitor II |